Spinal Cord Stimulation in Patients With Post-Laminectomy Syndrome in Testing Phase

Failed Back Surgery Syndrome Clinical Trial

Official title:

Randomized, Single-blind, Multicenter, Crossover, Controlled Clinical Trial to Compare Difference on the Visual Analogue Scale With Two Modes of Spinal Cord Stimulation in Patients With Post-Laminectomy Syndrome in Testing Phase

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03702010
• Other study ID #: EST-MED-2018-01
• Secondary ID: E.C.P.S. 18/1398
• Status: Completed
• Phase: N/A
• Start date: November 20, 2018
• Est. completion date: July 1, 2020

Study information

• Verified date: August 2021
• Source: Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Traditionally, pain relief through spinal cord stimulation has been associated with the appearance of paresthesia in the affected area. Several parameters are set to maximize the overexposure zone, such as frequency,and pulse width. Although this technique has improved pain in many patients, paresthesia itself can be uncomfortable. Traditionally, the occurrence of paresthesias has been considered to be a predictor of success in pain elimination, while the non-occurrence of paresthesias would indicate failure. So far, few studies have reported pain relief below the threshold of onset of paresthesia. Some clinical trials for pathologies other than the one considered in this study have achieved relief below the threshold by reducing the amplitude of the stimulus. Recently, however, it has been observed in a pilot study that, by increasing the frequency of spinal cord stimulation to 1 kilohertz, it is possible to significantly improve pain relief compared to less frequent conventional stimulation based on the occurrence of paresthesias.

A recent review by the Cochrane Library concluded that conventional spinal cord stimulation for pain relief of Failed Back Surgery Syndrome (or FBSS) requires further clinical studies and better designs to demonstrate its superiority over other therapeutic options. Therefore, although spinal cord stimulation is accepted by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), new techniques are being introduced that offer better results in terms of pain relief. Among these techniques, there is the high frequency mode, which allows avoiding the annoying sensation of paresthesia that substitutes pain with the conventional technique. In order to provide greater rigour and scientific quality, the present study is proposed, in which the conventional spinal cord stimulation (CME) technique (control branch or CME) is compared with paresthesias and a standard frequency (60 hertz) with a high frequency (1000 hertz) EVOLVE system (Evolve workflow - standardized guidance to simplify the trial and implant experience and optimize patient outcomes) (experimental branch or EME) by means of a design with a high degree of scientific evidence, randomising the global sample of patients to each of the two branches of stimulation in the study (blind to the patient) and crossing the branches after a period of washing

Recruitment information / eligibility

• Status: Completed
• Enrollment: 27
• Est. completion date: July 1, 2020
• Est. primary completion date: July 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients over 18 years of age.

• Patients with FBSS syndrome with leg pain or leg and back pain.

• Get a score on the visual analogue scale (VAS) = 7.

• Have received medical pharmacological treatment for at least 6 months after back surgery.

• The patient has signed the informed consent form.

Exclusion Criteria:

• Patients under 18 years of age.

• Patients who require a diathermic energy source (microwave, ultrasound or short wave).

• Patients with a pacemaker.

• Patients carrying a defibrillator.

• Patient with a cochlear implant.

• Patients with other active implanted devices.

• Patients who are scheduled to have any of the following procedures during the study period: an MRI, defibrillation or cardioversion, electrocautery, lithotripsy, radiofrequency or microwave ablation, and any other high-frequency ultrasound procedure,

• Women of childbearing age who do not use adequate contraception.

• Pregnant or breastfeeding.

• Participation in another trial.

• Patients who have expressed a desire not to participate in the study and have not formed informed consent.

• Patients with a failed spinal cord stimulation implant previously

Related Conditions & MeSH terms

• Failed Back Surgery Syndrome
• Laminectomy
• Post-laminectomy Syndrome
• Postoperative Complications
• Spinal Cord Injuries
• Spinal Cord Syndrome
• Spinal Diseases
• Syndrome

Intervention

Device:
• spinal cord stimulation conventional
If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.
• spinal cord stimulation experimental
If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.

Locations

Country	Name	City	State
Spain	Hospital San Pedro de Logroño	Logroño	La Rioja
Spain	Complejo Asistencial Universitario de Salamanca	Salamanca

Sponsors (2)

Lead Sponsor	Collaborator
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León	Instituto de Investigación Biomédica de Salamanca

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Comparing Visual Analogue Scale (VAS)	Visual analogue scale (VAS) at the end of each test phase (either with conventional spinal cord stimulation or with EVOLVE). VAS consists of a 10 centimeter (cm) line, whose ends are defined as the extreme limits of pain (left end corresponds with the absence of pain and the right end with the maximum amount of pain).; The patient is asked to point out in the line the place that better correspond to his/her pain, ranging from 0 to 10.	Baseline, After first stimulation (5days), after washout and second stimulation (12 days), After 30-day follow-up (42 days)
Secondary	Change (%) in VAS Scale at the End of Treatment.	Change (%) in Visual Analogue Scale (VAS) at the end of treatment.; ? = [(VAS Initial Visit - VAS Final Visit) / VAS initial visit] *100; Please note that positive values indicate a decrease in the VAS scale, which would indicate pain relief, as it was calculated as the value at the earlier time point minus the value at the later time point.	After first stimulation (Five days after baseline), After second stimulation (12 days after baseline), at the end of follow-up (42 days after baseline)
Secondary	Evaluation Disability	Oswestry Disability Index of the patients: it is a questionnaire consisting of 10 questions with 6 possible answers each. Every answer gives a punctuation from 0 (less disability) to 5 (more disability).; This scale is expressed in percentage in which 0 percentage (%) would the least disability and 100 percentage (%) would represent the maximum disability.	Baseline, After first stimulation (+5 days), After washout and second stimulation (+12 days), at the end of follow-up (+42days)
Secondary	Number of Participants With Adverse Events in Each Arm	Considering as an adverse event those that result in death, or in severe harm to patient's health (lesion that threatens life, permanent harm on an organ or corporal function, or process that needs a medical or surgical intervention to avoid permanent harm)	42 days from baseline